These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31325529)

  • 21. Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
    Marampon F; Leoni F; Mancini A; Pietrantoni I; Codenotti S; Ferella L; Megiorni F; Porro G; Galbiati E; Pozzi P; Mascagni P; Budillon A; Maggio R; Tombolini V; Fanzani A; Gravina GL; Festuccia C
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):393-409. PubMed ID: 30474756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trichostatin A Inhibits Rhabdomyosarcoma Proliferation and Induces Differentiation through MyomiR Reactivation.
    Tarnowski M; Tkacz M; Kopytko P; Bujak J; Piotrowska K; Pawlik A
    Folia Biol (Praha); 2019; 65(1):43-52. PubMed ID: 31171081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
    Wei Y; Zhou F; Lin Z; Shi L; Huang A; Liu T; Yu D; Wu G
    Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
    Huang HL; Peng CY; Lai MJ; Chen CH; Lee HY; Wang JC; Liou JP; Pan SL; Teng CM
    Oncotarget; 2015 Mar; 6(7):4976-91. PubMed ID: 25669976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
    Heinicke U; Fulda S
    Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
    Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
    J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repair.
    Codenotti S; Marampon F; Triggiani L; Bonù ML; Magrini SM; Ceccaroli P; Guescini M; Gastaldello S; Tombolini V; Poliani PL; Asperti M; Poli M; Monti E; Fanzani A
    Cancer Lett; 2021 May; 505():1-12. PubMed ID: 33610729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
    Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
    Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
    Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
    Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
    Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
    Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
    Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
    Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.
    Heinicke U; Kupka J; Fulda S
    Oncotarget; 2015 Nov; 6(35):37836-51. PubMed ID: 26473375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
    Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
    Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
    Haydn T; Metzger E; Schuele R; Fulda S
    Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells.
    Zhang M; Truscott J; Davie J
    Mol Cancer; 2013 Nov; 12(1):150. PubMed ID: 24279793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.
    Dobson CC; Naing T; Beug ST; Faye MD; Chabot J; St-Jean M; Walker DE; LaCasse EC; Stojdl DF; Korneluk RG; Holcik M
    Oncotarget; 2017 Jan; 8(2):3495-3508. PubMed ID: 27966453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.